Antimicrobial Efficacy Testing: Standards, Methods & Laboratory Services
What Is Antimicrobial Efficacy Testing?
Antimicrobial efficacy testing quantifies the ability of antimicrobial agents, treated surfaces, coatings, textiles, and medical devices to kill, inhibit, or reduce viable populations of bacteria, fungi, viruses, and spores under defined test conditions. It is a mandatory regulatory requirement for antimicrobial product registration, medical device clearance, and textile certification in the medical device, pharmaceutical, textiles, and coatings industries. Without validated efficacy data, antimicrobial claims cannot legally appear on product labels or marketing materials in regulated markets.
Regulatory Framework for Antimicrobial Claims
EPA Registration (United States)
Antimicrobial pesticide products — disinfectants, sanitizers, sterilants — are regulated by the EPA under FIFRA (Federal Insecticide, Fungicide, and Rodenticide Act). EPA 810 series test guidelines define required efficacy protocols for different product categories: hospital disinfectants, tuberculocidal products, virucidal claims, and sporicidal claims. Each requires specific test methods and pass criteria.
FDA 510(k) and PMA for Antimicrobial Medical Devices
Medical devices with antimicrobial surface claims require FDA clearance demonstrating efficacy per ISO 22196, ASTM E2180, or JIS Z 2801 alongside standard biocompatibility (ISO 10993) and performance testing. Zone of inhibition, time-kill, and quantitative surface methods provide supporting evidence for specific antimicrobial claims.
EU Biocidal Products Regulation (BPR 528/2012)
All biocidal products marketed in the EU require BPR authorization, which includes mandatory efficacy testing per EN 1276, EN 13697, EN 14476 (virucidal), and related European Norm (EN) standards — often with different methodologies and pass criteria than those of EPA methods.
Key Antimicrobial Efficacy Test Methods
Quantitative Suspension Tests (EN 1276 / ASTM E1054)
Bacterial suspensions are exposed to an antimicrobial agent at a defined concentration and contact time, then quantitatively cultured to determine the log₁₀ reduction. EN 1276 requires ≥5 log₁₀ reduction of Staphylococcus aureus, Pseudomonas aeruginosa, Enterococcus hirae, and Escherichia coli at 20°C within 5 minutes for a bactericidal claim.
Hard Surface Carrier Test (EPA MB-01-18 / ASTM E2197)
Inoculated hard-surface carriers (stainless steel cylinders or glass penicylinders) are treated with the disinfectant at the use dilution and contact time, then cultured to determine the log₁₀ reduction. Required for EPA hospital disinfectant, tuberculocidal, and hard surface virucidal label claims.
ISO 22196 — Antibacterial Activity of Plastics and Surfaces
ISO 22196 measures the antibacterial activity of non-porous plastic and other non-porous surfaces by inoculating test-organism suspensions under a film cover, incubating for 24 hours, and then enumerating survivors. A 2-log₁₀ (99%) reduction relative to the untreated control is the typical minimum claim threshold for antimicrobial plastic products.
ASTM E2180 — Antimicrobial Activity in Polymeric and Hydrophobic Materials
ASTM E2180 evaluates antimicrobial performance of materials that may not support quantitative surface inoculation — hydrophobic polymers, textured surfaces, and porous materials — using a slurry challenge method under defined agitation and contact time conditions.
ISO 18184 — Antiviral Activity of Textiles
ISO 18184 quantifies the antiviral activity of textile products against influenza and other test viruses by comparing viral titer reduction on treated vs. untreated fabric specimens after a defined contact time and temperature.
Why Choose Infinita Lab for Antimicrobial Efficacy Testing?
Infinita Lab is a leading provider of antimicrobial efficacy testing services — including EPA, FDA, ISO 22196, ASTM E2180, EN 1276, and custom protocols — across a nationwide accredited lab network, with fast turnaround times and comprehensive project management.
Looking for a trusted partner to achieve your research goals? Schedule a meeting with us, send us a request, or call us at (888) 878-3090. [Request a Quote]
Frequently Asked Questions
What log reduction is required for a disinfectant to claim hospital-grade efficacy? EPA hospital disinfectant registration requires ≥3 log₁₀ (99.9%) reduction of Staphylococcus aureus and Pseudomonas aeruginosa in carrier tests. Tuberculocidal claims require ≥3 log₁₀ reduction of Mycobacterium bovis BCG. Virucidal claims require ≥3 log₁₀ reduction of envelope and non-enveloped virus surrogate organisms per EPA MB-28-01.
What organisms are used in standard antimicrobial efficacy testing? Standard test organisms include Staphylococcus aureus (ATCC 6538), Escherichia coli (ATCC 11229), Pseudomonas aeruginosa (ATCC 15442), Klebsiella pneumoniae, Candida albicans (fungicidal claims), Mycobacterium bovis BCG (tuberculocidal), and Murine norovirus or MS2 bacteriophage (virucidal claims). Clinical isolates of methicillin-resistant S. aureus (MRSA) and other priority pathogens are increasingly required.
What is the difference between bacteriostatic and bactericidal activity? Bactericidal activity kills bacteria — the organism is permanently inactivated and cannot regrow after removal of the antimicrobial agent. Bacteriostatic activity inhibits growth while the agent is present — bacteria can resume growth when the agent is removed. Regulatory claims for disinfectants and antimicrobial surfaces require bactericidal (not merely bacteriostatic) activity demonstrated by kill assays.
What test method is used for antimicrobial textiles? ISO 18184 (antiviral activity), ISO 20743 (antibacterial activity of textiles), and AATCC 100 (antibacterial finishes on textile materials) are the primary standards for antimicrobial textile testing. ISO 20743 and AATCC 100 both measure log₁₀ reduction of bacterial populations on treated fabric specimens versus untreated controls.
What regulatory evidence is needed to claim antiviral efficacy against SARS-CoV-2? EPA's Emerging Pathogen Policy accepts efficacy data from harder-to-kill surrogate viruses (murine norovirus for non-enveloped viruses; human coronavirus 229E for enveloped viruses) to support SARS-CoV-2 label claims. Direct testing against SARS-CoV-2 using ASTM E1052 or EPA MB-28-01 adapted protocols in a BSL-3 facility provides definitive efficacy data.
